Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Stagg J, Golden E, Wennerberg E, Demaria S. The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy. Sci Immunol. 2023;8(85):eabq3015.

Helfgott DC, Racine-Brzostek S, Short KJ, Zhao Z, Christos P, Nino I, et al. Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome. Leuk Lymphoma. 2023;64(3):662-670.

Assaad MA, Shin N, Sigouros M, Manohar J, Antysheva Z, Kotlov N, et al. Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis. Front Oncol. 2023;13:1274163.

Zhao Z, Kumanovics A, Love T, Melanson SE, Meng QH, Wu AH, et al. T Cell Responses Correlate with Self-Reported Disease Severity and Neutralizing Antibody Responses Predict Protection against SARS-CoV-2 Breakthrough Infection. Viruses. 2023;15(3).

Folarin OS, Siddiqui MT. Are we on track for diagnosing high-grade urothelial carcinoma with a minimum quantity of five malignant cells in lower tract specimens? Critical analysis of The Paris System Quantitation Criteria. Cancer Cytopathol. 2023;131(11):708-715.

Marx CE, Schenker C, Xu Y, Salvatore SP, Kahn SR, Garcia D, et al. Accuracy and interrater agreement of death event adjudications by physician trainees: validation of the ISTH definition of pulmonary embolism-related death in an autopsy cohort. J Thromb Haemost. 2023;21(10):2908-2912.

Elhadad S, Redmond D, Tan A, Huang J, Rodriguez BL, Racine-Brzostek SE, et al. Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies. Thromb Res. 2023;225:47-56.

Nuzzo PV, Pederzoli F, Saieva C, Zanardi E, Fotia G, Malgeri A, et al. Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. J Transl Med. 2023;21(1):75.

Magro CM, Kalomeris T, Roberts A. Primary cutaneous blastic marginal zone lymphoma: A comprehensive clinical, light microscopic, phenotypic and cytogenetic appraisal. Ann Diagn Pathol. 2023;63:152101.

van der Mijn JC, Laursen KB, Fu L, Khani F, Dow LE, Nowak DG, et al. Novel genetically engineered mouse models for clear cell renal cell carcinoma. Sci Rep. 2023;13(1):8246.